119540-35-1

Upstream product

• 3471-32-7 4-Methoxyphenylhydrazine 
• 119540-31-7 3-Carboethoxy-5-(4-chlorophenyl)-1-(4-methoxyphenyl)pyrazole 
• 99-91-2 para-chloroacetophenone 
• 119540-33-9 5-(4-Chlorophenyl)-3-hydroxymethyl-1-(4-methoxyphenyl)pyrazole 

Downstream Products

• 119540-37-3 Ethyl 3-<5-(4-chlorophenyl)-1-(4-methoxyphenyl)-3-pyrazolyl>-2-(4-chlorophenyl)propanoate 
• 119540-40-8 3-[5-(4-Chloro-phenyl)-1-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-2-(4-methoxy-phenyl)-propionic acid ethyl ester 
• 119540-39-5 3-[5-(4-Chloro-phenyl)-1-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-2-(3,4-dimethoxy-phenyl)-propionic acid ethyl ester 
• 119540-38-4 3-[5-(4-Chloro-phenyl)-1-(4-methoxy-phenyl)-1H-pyrazol-3-yl]-2-phenyl-propionic acid ethyl ester 

Relevant academic research and scientific papers

SAR studies of 1,5-diarylpyrazole-based CCK1 receptor antagonists

A high throughput screening campaign revealed compound 1 as a potent antagonist of the human CCK1 receptor. Here, we report the syntheses and SAR studies of 1,5-diarylpyrazole analogs with various structural modifications of the alkane side cha

Pyrazole CCK1 receptor antagonists. Part 1: Solution-phase library synthesis and determination of Free-Wilson additivity

High throughput screening revealed compound 1 as a potent antagonist of the CCK1 receptor. Evaluation of the CCK1 SAR in a series of these diarylpyrazole antagonists was conducted in a matrix synthesis format revealing additive (Free

Pharmacologically active 2- and 3-substituted (1',5'-diaryl-3-pyrazolyl)-N-hydroxypropanamides

2- and 3-substituted (1',5'-diaryl-3'-pyrazolyl)-N-hydroxypropanamides, a method for their preparation, compositions containing the same and methods of their use are disclosed. The N-hydroxypropanamides are useful in alleviating inflammatory and cardiovascular disorders in mammals.